Kevin Lanclos, MD
Internal Medicine · Social Circle, GANPI 1841297793
Payments from drug & device makers
Across 228 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$533
- Lilly USA, LLC$483
- Novo Nordisk$459
- AstraZeneca$441
- GSK$226
- Amgen$168
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,92698%
- Education$652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 31 | $533 |
| Lilly USA, LLC | 27 | $483 |
| Novo Nordisk | 25 | $459 |
| AstraZeneca(2 entities) | 27 | $441 |
| GSK | 12 | $226 |
| Amgen(2 entities) | 11 | $168 |
| Boehringer Ingelheim | 9 | $158 |
| Merck | 10 | $152 |
| Johnson & Johnson | 9 | $150 |
| Exact Sciences | 8 | $149 |
| Abbott | 6 | $113 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $113 |
| Dexcom, Inc. | 4 | $91 |
| Novartis | 5 | $91 |
| Bayer | 4 | $75 |
| AbbVie | 4 | $72 |
| Sanofi-aventis U.S. LLC | 3 | $55 |
| Kowa Pharmaceuticals America, Inc. | 3 | $47 |
| Amarin Pharma, Inc. | 3 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Corcept Therapeutics | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Astellas Pharma US Inc | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Exeltis, USA Inc. | 1 | $13 |
How this compares
$3,991 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 72 | $124,153 |
| EliquisApixaban | 133 | $114,654 |
| XareltoRivaroxaban | 98 | $87,434 |
| MounjaroTirzepatide | 54 | $79,768 |
| FarxigaDapagliflozin Propanediol | 58 | $56,435 |
| TrulicityDulaglutide | 34 | $46,974 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $38,005 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $15,052 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 33 | $10,965 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $7,108 |
| Valsartan | 196 | $7,032 |
| Pravastatin Sodium | 455 | $5,995 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $5,532 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $5,358 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 36 | $5,333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $483 | $126,74288 claims |
| Novo NordiskOzempic | $459 | $124,15372 claims |
| PfizerEliquis | $533 | $114,654133 claims |
| Johnson & JohnsonXarelto | $150 | $87,43498 claims |
| AstraZenecaFarxiga | $441 | $56,43558 claims |
| GSKTrelegy Ellipta | $226 | $38,00549 claims |
| AbbVieSynthroid | $72 | $1,72424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Social Circle
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.